HEICO (HEI) PT Raised to $100 at Canaccord Genuity Following 2Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
UPDATE: SunTrust Downgrades HEICO (HEI) to Hold
May 28, 2020 6:04 AM EDT(Updated - May 28, 2020 8:48 AM EDT)
(updated to add analyst comments)
SunTrust analyst Michael Ciarmoli downgraded HEICO (NYSE: HEI) from Buy to Hold with a price target of $95 (from $70).
The analyst commented, "HEI has surged 70% from the March... More
After-Hours Stock Movers 05/26: (CPIX) (HTZ) (STNE) Higher; (VSAT) (KEYS) (IIPR) Lower (more...)
May 26, 2020 5:49 PM EDTToday's After-Hours Stock Movers:
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) 37% HIGHER; announces a new publication in Drugs - Real World Outcomes1, detailing the positive clinical outcomes with Vibativ® in treating patients with bacteremia or endocarditis. Vibativ® (telavancin) is a potent, FDA-approved anti-infective for the treatment of serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia. It is also approved for complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.
Hertz Global Holdings,... More
Heico Corp. (HEI) Tops Q2 EPS by 11c, Revenues Beat
May 26, 2020 4:18 PM EDTHeico Corp. (NYSE: HEI) reported Q2 EPS of $0.55, $0.11 better than the analyst estimate of $0.44. Revenue for the quarter came in at $468.1 million versus the consensus estimate of $462.86 million.
In the second quarter of fiscal 2020, net income decreased 8% to $75.5 million, or 55 cents per diluted share, as compared to $81.8 million, or 60 cents per diluted share, in the second quarter of fiscal 2019.In the second quarter of fiscal 2020, operating income decreased 9% to $108.2 million, as compared to $119.2 million in the second quarter of fiscal 2019.The Company's consolidated operating margin was 23.1% in both the second... More